View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

Eyepoint and Ocumension sign license agreement in China for Dexycu

US-based Eyepoint Pharmaceuticals has signed an exclusive license agreement with Chinese Ocumension Therapeutics for the development and commercialisation of the former’s Dexycu (dexamethasone intraocular suspension) 9% in mainland China, Macau, Hong Kong and Taiwan.

By Allie Nawrat

US-based Eyepoint Pharmaceuticals has signed an exclusive license agreement with Chinese Ocumension Therapeutics for the development and commercialisation of the former’s Dexycu (dexamethasone intraocular suspension) 9% in mainland China, Macau, Hong Kong and Taiwan.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

According to the terms of the agreement, Eyepoint will receive an upfront payment of $2m from Ocumension, as well as royalties on all Dexycu product sales by the Chinese company. The US company will also be eligible to receive an additional $12m if certain future development, regulatory and commercial sales milestones are reached by Ocumension.

Eyepoint will be the exclusive supplier of Dexycu to Ocumension in these Asian geographies.

Dexycu is the first intraocular product approved in the US for the treatment of post-surgery inflammation; it received US Food and Drug Administration approval in February 2018. It was created using Eyepoint’s proprietary Verisome technology, which allows for the sustained release of small molecules over one to six months after only a single injection.

Ocumension CEO Ye Liu said: “Dexycu is an important addition to our growing portfolio of ocular disease treatments for patients in the greater China region and continues our strong partnership with EyePoint.

“There is a need for innovation to replace the burdensome steroid eye drop regimen prescribed for post-cataract surgery inflammation which has low patient compliance due to its complex dosing schedule.

“Dexycu has the potential to become the new standard of care as a single-dose, sustained release therapeutic option that provides long-lasting benefit for up to 22 days.”

Eyepoint CEO and president Nancy Lurker added: “Ocumension shares our common goal of rapidly advancing innovative ocular disease therapies to address growing areas of unmet need and improve the standard of care for patients.

“We are pleased to partner with their team to expand the global reach of Dexycu in the emerging Chinese market on behalf of patients in need.”

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology